bioMerieux SA (BIM.PA): analysis and signal as of September 7, 2026
In short
The signal is weak with a score of 1,5. Solid operational quality and the defensive sector are offset by a marked technical weakness.
- Current signal
- weak (vote 2/3)
- Deterministic score
- +1.5 → signal expected by the scale : moderate (September 10, 2026)
- Layers
- fundamentals : positive, price : neutral, risks : neutral
Triggered rules
| Rule | Weight |
|---|---|
| favors high gross profitability (gross profit / assets), a robust predictor of returns | +1.0 |
| moderately favors an asset with robust operating profitability (RMW factor), cross-check with accounting quality (possible manipulation) | +0.5 |
Thesis
bioMérieux reports an EBITDA margin of 31,4 % and a free cash flow of 12-13 % of revenue. The defensive healthcare sector is favored by the macro regime. The stock is down 35,95 % over one year. The bullish consensus targets a median objective of 100 to 125 EUR. The technical layer remains weak. The negative overnight move imposes patience.
Bull case
The EBITDA margin of 31,4 % and the free cash flow of 12-13 % of revenue support the thesis. The 2026 guidance is confirmed with organic revenue growth of 8 to 11 %. EBITDA is guided between 490 and 505 M€. The PER is around 27x under the analysts' median target. A buyback of 7,5 M€ is underway. The EXPANSION regime favors the defensive healthcare sector.
Bear case
The price of 72,90 EUR is 14,5 % below the 200-session moving average. The one-year loss reaches 35,95 %. The overnight move is negative at 8,5 bp/j. Medium-term targets are lowered. The first-half EBITDA margin is below the guidance range. The price is below the average buyback price of 172,30 EUR. The BCE rising to 2,25 % weighs on rate-sensitive stocks.
Scenarios
The bullish scenario has a 40 % probability with a target of 100 EUR. The central scenario has a 40 % probability. The bearish scenario has a 20 % probability with a maximum loss of 13 % in case of a close below 65 EUR.
Risks
Technical weakness persists. The price remains below the 200-session moving average. The first-half EBITDA margin is below the guidance range. The BCE rising weighs on rate-sensitive stocks. The negative overnight move continues to weigh on the stock.
Upcoming catalysts
| Date | Description |
|---|---|
| Q3 2026 results and BIOFIRE US market update | |
| AACC congress: new BIOFIRE Spotfire applications |
Signal history (last 12 months)
| Date | Signal | New fact |
|---|---|---|
| weak (2/3) | The price of bioMérieux SA (BIM.PA) is 72,90 EUR on 07/09/2026, compared to 75,60 EUR on 02/09/2026. The gap of 3,57 % is insufficient to modify the verdict. No new fact is dated. | |
| weak (3/3) | No new fact is dated since the verdict of 2026-08-31. Direct sources remain blocked by Cloudflare and DataDome. The S1 2026 data are still marked perime possible. The deterministic score moved from plus 3,00 to plus 1,50 without a new catalyst to justify a change in SIGNAL or ACTION. | |
| weak (single draw, outside the three-draw protocol) | unchanged | |
| weak (single draw, outside the three-draw protocol) | unchanged |
Frequently asked questions
What is the current signal for bioMérieux?
The signal is weak with a vote of 2/3 and a score of 1,5. The technical layer is weak. The overnight move is negative. The defensive healthcare sector is favored by the macro regime. The bullish consensus targets 100 to 125 EUR.
What are the main bullish arguments?
The EBITDA margin is 31,4 %. Free cash flow represents 12-13 % of revenue. The 2026 guidance is confirmed with organic revenue growth of 8 to 11 %. EBITDA is guided between 490 and 505 M€. A buyback of 7,5 M€ is underway.
What are the main bearish arguments?
The price of 72,90 EUR is 14,5 % below the 200-session moving average. The one-year loss reaches 35,95 %. The overnight move is negative at 8,5 bp/j. The first-half EBITDA margin is below the guidance range. The BCE rising to 2,25 % weighs on rate-sensitive stocks.
What are the probable scenarios?
The bullish scenario has a 40 % probability with a target of 100 EUR. The central scenario has a 40 % probability. The bearish scenario has a 20 % probability with a maximum loss of 13 % in case of a close below 65 EUR.
What is the main risk?
Technical weakness persists. The price remains below the 200-session moving average. The first-half EBITDA margin is below the guidance range. The BCE rising weighs on rate-sensitive stocks. The negative overnight move continues to weigh on the stock.
Sources
The official filings below are the issuer's own, matched to this stock by its identifier (LEI, CIK or ISIN). The figures quoted above come from an automated arbitration: they have not been re-checked one by one.
- — Août 2026 - Déclaration sur le nombre d'actions composant le capital social et sur le nombre de droits de vote correspondant (AMF · Informations réglementées continues)
- — Rapport Financier Semestriel 2026 (AMF · Informations réglementées périodiques)
- — Rapport Financier Semestriel 2026 (AMF · Informations réglementées périodiques)
- — Juillet 2026 - Déclaration sur le nombre d'actions composant le capital social et sur le nombre de droits de vote correspondant (AMF · Informations réglementées continues)
- — Rapport Financier Semestriel 2026 (AMF · Informations réglementées périodiques)
Automated AI analysis: limitations and transparency
- This content is an automated analysis produced using artificial intelligence. Personal analysis for information purposes — no personalised investment advice. MMR content consists of general research. It does not take account of your financial circumstances, objectives or risk tolerance. Data, analyses and results, including those produced using artificial intelligence, may contain errors, be incomplete or become outdated. No return or outcome is guaranteed. All investments carry a risk of partial or total loss of capital. Past performance and simulations do not predict future results. Before making any decision, check information against original sources and, where necessary, consult an authorised professional. You remain responsible for your investment decisions. This notice does not exclude or limit any liability that cannot legally be excluded or limited.
- Tool and analysis: QDNA, Aurélien Ambert.
- Analysis (arbitration) completed on September 7, 2026; this page was completed on September 8, 2026 at 01:03 (UTC).
- Interests: no position in the stock analysed (BIM.PA) is recorded in the data consulted on (UTC). This does not confirm the absence of holdings or other interests. The situation at the analysis publication date has not been reconstructed.
- This declaration covers only recorded positions in this stock; it is not an exhaustive verification of other interests or remuneration.
- Methodology: analysis chain, score formula and scale described on the public methodology page.
- Analysis horizon: 2035.
See also
- Neighbouring stock in the same sector: AbbVie, Inc. (ABBV)
- All analysed stocks
- Public methodology